KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Income (2016 - 2025)

Historic Operating Income for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $57.5 million.

  • Jazz Pharmaceuticals' Operating Income fell 7789.9% to $57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$177.9 million, marking a year-over-year decrease of 12743.9%. This contributed to the annual value of $716.6 million for FY2024, which is 2386.01% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Operating Income is $57.5 million, which was down 7789.9% from -$686.4 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Operating Income ranged from a high of $260.2 million in Q3 2024 and a low of -$686.4 million during Q2 2025
  • Moreover, its 5-year median value for Operating Income was $86.5 million (2022), whereas its average is $42.8 million.
  • In the last 5 years, Jazz Pharmaceuticals' Operating Income crashed by 63338.6% in 2022 and then skyrocketed by 59616.77% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Operating Income (Quarter) stood at $49.4 million in 2021, then crashed by 633.39% to -$263.4 million in 2022, then skyrocketed by 146.51% to $122.5 million in 2023, then surged by 55.73% to $190.8 million in 2024, then tumbled by 69.85% to $57.5 million in 2025.
  • Its last three reported values are $57.5 million in Q3 2025, -$686.4 million for Q2 2025, and $190.8 million during Q4 2024.